China SXT Pharmaceuticals, Inc.
SXTC
$1.08
-$0.04-3.57%
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 23.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 23.08% | |||
| Cost of Revenue | 0.00% | 52.58% | |||
| Gross Profit | 0.00% | -14.32% | |||
| SG&A Expenses | 0.00% | 116.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.00% | 111.22% | |||
| Operating Income | 0.00% | -127.60% | |||
| Income Before Tax | 0.00% | -118.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.00% | -118.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | -118.37% | |||
| EBIT | 0.00% | -127.60% | |||
| EBITDA | 0.00% | -133.05% | |||
| EPS Basic | 0.00% | -87.96% | |||
| Normalized Basic EPS | 0.00% | -104.02% | |||
| EPS Diluted | 0.00% | -87.96% | |||
| Normalized Diluted EPS | 0.00% | -104.02% | |||
| Average Basic Shares Outstanding | 0.00% | 16.20% | |||
| Average Diluted Shares Outstanding | 0.00% | 16.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
